用于妇科癌症早期检测的血清生物标志物。
Serum biomarkers for early detection of gynecologic cancers.
机构信息
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
出版信息
Cancers (Basel). 2010 Jun 14;2(2):1312-27. doi: 10.3390/cancers2021312.
Abstract
Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unreliable; SCC is elevated in cervical squamous cell carcinomas ranging from 28-85% of the time. Recent proteomics-based analyses show great promise for the discovery of new and more useful biomarkers. In this review, we will discuss the currently utilized serum tumor markers for gynecologic cancers and the novel biomarkers that are now under investigation.
摘要
卵巢癌、子宫内膜癌和宫颈癌是女性生殖系统最常见的三种恶性肿瘤。CA125 是历史上卵巢癌最可靠的血清标志物，在 50%的早期卵巢肿瘤中升高。对于子宫内膜癌，目前还没有确定的血清标志物。SCC 是鳞状细胞癌最好的研究血清标志物，但不可靠；SCC 在宫颈鳞状细胞癌中的升高率为 28-85%。最近基于蛋白质组学的分析显示了发现新的和更有用的生物标志物的巨大潜力。在这篇综述中，我们将讨论目前用于妇科癌症的血清肿瘤标志物和正在研究的新的生物标志物。
相似文献
1
Serum biomarkers for early detection of gynecologic cancers.用于妇科癌症早期检测的血清生物标志物。
Cancers (Basel). 2010 Jun 14;2(2):1312-27. doi: 10.3390/cancers2021312.
2
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.卵巢癌的筛查、诊断和监测生物标志物。
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):1902-12. doi: 10.1158/1055-9965.EPI-12-0646. Epub 2012 Sep 7.
3
Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Biomed Pharmacother. 2004 Jan;58(1):24-38. doi: 10.1016/j.biopha.2003.11.003.
4
Combination assay of urinary beta-core fragment of human chorionic gonadotropin with serum tumor markers in gynecologic cancers.人绒毛膜促性腺激素尿β-核心片段与血清肿瘤标志物联合检测在妇科癌症中的应用
Jpn J Cancer Res. 1995 Aug;86(8):783-9. doi: 10.1111/j.1349-7006.1995.tb02469.x.
5
Serum squamous cell carcinoma antigen in gynecologic malignancies with special reference to cervical cancer.妇科恶性肿瘤中的血清鳞状细胞癌抗原，特别提及宫颈癌。
Taiwan Yi Xue Hui Za Zhi. 1989 Aug;88(8):797-800.
6
Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.个性化循环肿瘤DNA生物标志物可动态预测妇科癌症的治疗反应和生存情况。
PLoS One. 2015 Dec 30;10(12):e0145754. doi: 10.1371/journal.pone.0145754. eCollection 2015.
7
Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.评估七种不同肿瘤标志物以建立妇科恶性肿瘤的肿瘤标志物组合。
Eur J Gynaecol Oncol. 1989;10(6):395-405.
8
Clinical statistics of gynecologic cancers in Japan.日本妇科癌症的临床统计数据。
J Gynecol Oncol. 2017 Mar;28(2):e32. doi: 10.3802/jgo.2017.28.e32. Epub 2017 Feb 10.
9
Skin metastases of gynecologic adenocarcinomas affect serum levels of hCGbeta but not those of SCC antigen.
Tumour Biol. 1999 Sep-Oct;20(5):251-5. doi: 10.1159/000030071.
10
Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients.妇科癌症的腹腔冲洗细胞学检查：355例患者的长期随访
J Natl Cancer Inst. 1996 Jul 17;88(14):980-7. doi: 10.1093/jnci/88.14.980.
引用本文的文献
1
Adenomyosis-associated uterine rupture and pulmonary endometriosis mimicking advanced-stage uterine malignancy in an adolescent female: A case report.一名青春期女性中与子宫腺肌病相关的子宫破裂及酷似晚期子宫恶性肿瘤的肺子宫内膜异位症：病例报告
World J Clin Cases. 2025 Oct 6;13(28):109536. doi: 10.12998/wjcc.v13.i28.109536.
2
Splenic Metastasis of Endometrial Carcinoma Manifesting as a Hemorrhagic Splenic Cyst 17 Years After Surgery.子宫内膜癌脾转移表现为术后17年出现的脾出血性囊肿
Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70118. doi: 10.1111/ases.70118.
3
Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer.所选生物标志物及其组合在卵巢癌诊断中的敏感性和特异性。
Diagnostics (Basel). 2024 Apr 30;14(9):949. doi: 10.3390/diagnostics14090949.
4
Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review.基于代谢组学的子宫内膜癌诊断与预后方法：综述
Cancers (Basel). 2023 Dec 29;16(1):185. doi: 10.3390/cancers16010185.
5
Integrated analysis identifies RAC3 as an immune-related prognostic biomarker associated with chemotherapy sensitivity in endometrial cancer.整合分析鉴定 RAC3 为一种与子宫内膜癌化疗敏感性相关的免疫相关预后生物标志物。
J Cell Mol Med. 2023 Aug;27(16):2385-2397. doi: 10.1111/jcmm.17824. Epub 2023 Jun 29.
6
Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer.评估卵巢癌患者选定免疫和分子参数测定的潜在诊断效用。
Diagnostics (Basel). 2023 May 12;13(10):1714. doi: 10.3390/diagnostics13101714.
7
Serum lipidomic profiling by UHPLC-MS/MS may be able to detect early-stage endometrial cancer.通过超高效液相色谱-串联质谱法进行血清脂质组分析或许能够检测出早期子宫内膜癌。
Anal Bioanal Chem. 2023 Apr;415(10):1841-1854. doi: 10.1007/s00216-023-04586-x. Epub 2023 Feb 17.
8
Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer.长链非编码RNA MVIH的异位表达作为宫颈癌潜在的诊断生物标志物
Genes Cancer. 2022 Nov 23;13:52-59. doi: 10.18632/genesandcancer.224. eCollection 2022.
9
Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer.用于子宫内膜癌检测、预后评估及复发识别的代谢组学生物标志物
Metabolites. 2020 Jul 31;10(8):314. doi: 10.3390/metabo10080314.
10
Coordination of Nanoconjugation with an Antigen/Antibody for Efficient Detection of Gynecological Tumors.纳米缀合与抗原/抗体的协同作用以高效检测妇科肿瘤
J Anal Methods Chem. 2020 Mar 30;2020:6528572. doi: 10.1155/2020/6528572. eCollection 2020.
本文引用的文献
1
ACOG Practice Bulletin no. 109: Cervical cytology screening.美国妇产科医师学会实践公告第109号：宫颈细胞学筛查
Obstet Gynecol. 2009 Dec;114(6):1409-1420. doi: 10.1097/AOG.0b013e3181c6f8a4.
2
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.评估选定卵巢癌生物标志物的领先时间：一项巢式病例对照研究。
J Natl Cancer Inst. 2010 Jan 6;102(1):26-38. doi: 10.1093/jnci/djp438. Epub 2009 Dec 30.
3
Serum amyloid A: a novel biomarker for endometrial cancer.血清淀粉样蛋白 A：子宫内膜癌的新型生物标志物。
Cancer. 2010 Feb 15;116(4):843-51. doi: 10.1002/cncr.24838.
4
A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics.利用新开发的糖蛋白质组学技术发现血清中癌症糖生物标志物的策略。
FEBS J. 2010 Jan;277(1):95-105. doi: 10.1111/j.1742-4658.2009.07430.x. Epub 2009 Nov 17.
5
Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.血清生物标志物在早期和晚期子宫内膜癌检测中的验证。
Am J Obstet Gynecol. 2010 Jan;202(1):73.e1-5. doi: 10.1016/j.ajog.2009.07.049. Epub 2009 Sep 20.
6
Identification of potential serum markers for endometrial cancer using protein expression profiling.采用蛋白质表达谱分析鉴定子宫内膜癌的潜在血清标志物。
J Cancer Res Clin Oncol. 2010 Mar;136(3):475-81. doi: 10.1007/s00432-009-0680-7. Epub 2009 Sep 16.
7
HE4 as a biomarker for ovarian and endometrial cancer management.人附睾蛋白4作为卵巢癌和子宫内膜癌管理的生物标志物。
Expert Rev Mol Diagn. 2009 Sep;9(6):555-66. doi: 10.1586/erm.09.39.
8
Validation of candidate serum ovarian cancer biomarkers for early detection.用于早期检测的候选血清卵巢癌生物标志物的验证。
Biomark Insights. 2007 Oct 16;2:369-75.
9
Clinical practice. Screening for ovarian cancer.临床实践。卵巢癌筛查。
N Engl J Med. 2009 Jul 9;361(2):170-7. doi: 10.1056/NEJMcp0901926.
10
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.血清淀粉样蛋白A（SAA）：一种用于子宫浆液性乳头状癌的新型生物标志物。
Br J Cancer. 2009 Jul 21;101(2):335-41. doi: 10.1038/sj.bjc.6605129. Epub 2009 Jun 16.
Zotero 插件